Skip to main content
COVID-19

Hepatitis C antivirals may fight SARS-CoV-2

Sofosbuvir/ledipasvir and nitazoxanide both appeared to clear SARS-CoV-2, the virus that causes COVID-19 in a preliminary trial, said Mohamed Medhat, lecturer in the department of gastroenterology and tropical medicine at Assiut University Hospitals in Assiut, Egypt.

SARS-CoV-2 shares similarities to the hepatitis C virus in the way it replicates, Medhat said. Molecular docking studies, which use computation to find ligands that bind to proteins, suggested that both sofosbuvir/ledipasvir and nitazoxanide might block key proteins in SARS-CoV-2.

Leave a Reply

error: